Timeline - Gefitinib - a novel targeted approach to treating cancer

被引：315

作者：

Herbst, RS

Fukuoka, M

Baselga, J

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA

[2] Kinki Univ, Sch Med, Dept Med Oncol, Osakasayama, Osaka 5898511, Japan

[3] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Med Oncol Serv, E-08193 Barcelona, Spain

来源：

NATURE REVIEWS CANCER | 2004年 / 4卷 / 12期

关键词：

D O I：

10.1038/nrc1506

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Twenty years after the epidermal growth factor receptor (EGFR) was identified as a potential anticancer target, the EGFR inhibitor gefitinib (Iressa; AstraZeneca) has been approved for the treatment of patients with advanced non-small-cell lung cancer in many countries. Studies have indicated its potential for treating patients with other types of solid tumours. Investigation of gefitinib has not only increased our knowledge about the biology of EGFR signalling, but is contributing to our evolving understanding of which tumours are EGFR dependent.

引用

页码：956 / 965

页数：10

共 88 条

[1] Radiation-induced and chemotherapy-induced pulmonary injury [J].

Abid, SH ;

Malhotra, V ;

Perry, MC .

CURRENT OPINION IN ONCOLOGY, 2001, 13 (04) :242-248

[2]

Albain K, 2002, BREAST CANCER RES TR, V76, pS33

[3] Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition [J].

Albanell, J ;

Rojo, F ;

Averbuch, S ;

Feyereislova, A ;

Mascaro, JM ;

Herbst, R ;

LoRusso, P ;

Rischin, D ;

Sauleda, S ;

Gee, J ;

Nicholson, RI ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :110-124

[4]

[Anonymous], [No title captured]

[5]

Bailey L. Renee, 2003, Proceedings of the American Association for Cancer Research Annual Meeting, V44, P1362

[6] Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer [J].

Barker, AJ ;

Gibson, KH ;

Grundy, W ;

Godfrey, AA ;

Barlow, JJ ;

Healy, MP ;

Woodburn, JR ;

Ashton, SE ;

Curry, BJ ;

Scarlett, L ;

Henthorn, L ;

Richards, L .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) :1911-1914

[7] Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: How do we go from INTACT to impact? [J].

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :759-761

[8] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[9]

BASELGA J, 2003, P AN M AM SOC CLIN, V22, P7

[10]

BASELGA J, 2000, SIGNAL, V1, P12

← 1 2 3 4 5 6 7 8 9 →